Compile Data Set for Download or QSAR
Report error Found 35 Enz. Inhib. hit(s) with all data for entry = 10655
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557564(US11358948, Compound I-2 | US11623932, Compound 2 ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557425(US11358948, Compound I-1 | US11623932, Compound 1 ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557622(US11358948, Compound I-62)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557625(US11358948, Compound I-64)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557623(US11358948, Compound I-63)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557636(US11358948, Compound I-66)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557632(US11358948, Compound I-65)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557638(US11358948, Compound I-68)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557637(US11358948, Compound I-67)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557639(US11358948, Compound I-69)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557425(US11358948, Compound I-1 | US11623932, Compound 1 ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 3: Untagged CRBN-DDB1 complex (final 50 nM) was mixed with Cy5-labeled thalidomide (final 20 nM) and various concentrations of compounds (a ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557564(US11358948, Compound I-2 | US11623932, Compound 2 ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 3: Untagged CRBN-DDB1 complex (final 50 nM) was mixed with Cy5-labeled thalidomide (final 20 nM) and various concentrations of compounds (a ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557642(US11358948, Compound I-72)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557641(US11358948, Compound I-71)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557644(US11358948, Compound I-74)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557646(US11358948, Compound I-76)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557645(US11358948, Compound I-75)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557650(US11358948, Compound I-78)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557647(US11358948, Compound I-77)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557653(US11358948, Compound I-80)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557651(US11358948, Compound I-79)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557657(US11358948, Compound I-82)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557654(US11358948, Compound I-81)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557659(US11358948, Compound I-84)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557658(US11358948, Compound I-83)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557661(US11358948, Compound I-86)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557660(US11358948, Compound I-85)
Affinity DataIC50: 1.00E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557620(US11358948, Compound I-29 | US11623932, Compound 2...)
Affinity DataIC50: 5.50E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557621(US11358948, Compound I-61)
Affinity DataIC50: 5.50E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557640(US11358948, Compound I-70)
Affinity DataIC50: 5.50E+3nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557643(US11358948, Compound I-73)
Affinity DataIC50: 5.50E+4nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557573(US11358948, Compound I-3 | US11623932, Compound 3)
Affinity DataIC50: 5.50E+4nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557620(US11358948, Compound I-29 | US11623932, Compound 2...)
Affinity DataIC50: 5.50E+4nMAssay Description:Table 3: Untagged CRBN-DDB1 complex (final 50 nM) was mixed with Cy5-labeled thalidomide (final 20 nM) and various concentrations of compounds (a ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557662(US11358948, Compound I-90)
Affinity DataIC50: 1.00E+5nMAssay Description:Table 2: Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557573(US11358948, Compound I-3 | US11623932, Compound 3)
Affinity DataIC50: 1.00E+5nMAssay Description:Table 3: Untagged CRBN-DDB1 complex (final 50 nM) was mixed with Cy5-labeled thalidomide (final 20 nM) and various concentrations of compounds (a ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
US Patent